The House Energy and Commerce Subcommittee on Oversight and Investigations today held the second part of a hearing on the rising cost of insulin, which featured witnesses from the nation’s three insulin manufacturers as well as three pharmacy benefit managers.
 
“It appears that there is limited competition and little incentive to keep prices at a level that patients can afford,” Committee Chairman Frank Pallone, D-N.J., said in opening remarks. “And perhaps there are incentives in place to keep raising prices. As a result, we are left with a drug that has been available for nearly 100 years, and yet the price tripled and then doubled in just the last couple decades. Clearly, something is not right here.”
 
During the first part of the hearing last week, diabetes care witnesses described the impact of rising insulin prices on patients.

Related News Articles

Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…
Headline
The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures.  Witness Ge Bai, an…